Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Special report
: The Fierce 50 of 2024
Alzheimer's
Biotech
Actinogen reports new data in bid to salvage depression drug
Xanamem missed its phase 2 primary endpoint in cognitive function, but new data show that the compound has hit secondary endpoints in depression.
Darren Incorvaia
Aug 26, 2024 11:03am
Researchers receive $6.9M NIA grant for tau-targeting drug
Aug 21, 2024 1:02pm
AC Immune sees 'landmark' potential in brain-penetrating ADC
Jul 31, 2024 10:00am
GLP-1 liraglutide reduces cognitive decline in Alzheimer's
Jul 30, 2024 1:29pm
BioVie cuts 'most de-risked program,' will seek partner
Mar 11, 2024 11:12am
Biogen's future Alzheimer's pipeline forms around tau, orals
Mar 7, 2024 10:25am